Ligand Pharmaceuticals Incorporated

NASDAQ
LGND
Stock
Yield per half year: -4.53%
Dividend yield: 0%
Sector: Healthcare

112.5 $

0 $ 0%
93.32 $
129.9 $

Min/max per year

Share chart Ligand Pharmaceuticals Incorporated

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

Main settings

IPO date
1992-11-18
ISIN
US53220K5048
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Дивиденд ао
0.456
Сайт

Grade

Underestimation
Title Value Grade
P/S 11.57 1
P/BV 2.33 6
P/E 24.35 6
Efficiency
Title Value Grade
ROA -0.4664 0
ROE -0.5266 0
ROIC 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0.5 5
Average dividend growth -1011.4 0
Debt
Title Value Grade
Debt/EBITDA 0.1655 10
Debt/Ratio 0.0075 10
Debt/Equity 0.1341 10
Growth impulse
Title Value Grade
Yield Revenue, % -10.34 0
Yield Ebitda, % 34.19 5
Yield EPS, % 24.27 4

Prices

Price Min. Max. Change Changes in the industry Changes in the index
Yesterday 112.5 $ 0 $ 0 $ 0 % 0 % 0 %
Week 113.42 $ 0 $ 0 $ -0.8111 % 0 % 0 %
Month 101.6 $ 112.5 $ 112.5 $ +10.73 % 0 % 0 %
Three month 104.27 $ 100.19 $ 115.39 $ +7.89 % 0 % 0 %
Half a year 117.84 $ 96.67 $ 122.23 $ -4.53 % 0 % 0 %
Year 106.54 $ 93.32 $ 129.9 $ +5.59 % 0 % 0 %
3 years 60.2 $ 48.1 $ 129.9 $ +86.88 % 0 % 0 %
5 years 117.93 $ 48.1 $ 215.83 $ -4.6 % 0 % 0 %
10 years 48.1 $ 48.1 $ 274.49 $ +233.91 % 0 % 0 %
Year to date 117.28 $ 96.67 $ 122.23 $ -4.08 % 0 % 0 %

Main owners

Contained in ETF

ETF
Share, %
Profitability for 1 year, %
Commission, %
Syntax Stratified SmallCap ETF 0.3841 -1.44 0.40
IndexIQ ETF Trust IQ U.S. Small Cap ETF 0.25 54.74 0.35
Future Tech ETF 0.1841 479.5 0.35
Principal Healthcare Innovators ETF 0.1841 -3.92 0.35
iShares Morningstar Small-Cap Growth ETF 0.04601 570.49 0.06
iShares Morningstar Small-Cap ETF 0.0404 301.34 0.25
iShares Morningstar Small-Cap Value ETF 0.03432 175.74 0.06
0.16225.210.26

Similar companies



Company management

Head Job title Payment Year of birth
Mr. Matthew E. Korenberg President & COO 831.77k 1975 (50 years)
Mr. Octavio Espinoza Chief Financial Officer 613.59k 1971 (54 years)
Mr. Andrew T. Reardon J.D. Chief Legal Officer & Secretary 614.87k 1975 (50 years)
Mr. Todd Pettingill Director of Corporate Development N/A
Dr. Keith Marschke Senior Vice President of Biology & Scientific Affairs N/A
Dr. Vincent D. Antle Senior Vice President of Technical Operations & QA - Capitsol N/A 1969 (56 years)
Mr. Paul J. Hadden Senior Vice President of Investments & Business Development N/A
Mr. Patrick Lucy Senior VP & CBO Protein Expression Business N/A
Mr. Todd C. Davis Ph.D. CEO & Director 1961 (64 years)
Michael Jeong Head of Investor Relations

About company

Address: United States, San Diego. CA, 3911 Sorrento Valley Boulevard - Open in google maps, Open in yandex maps
Website: https://www.ligand.com